DJ Transaction in own shares
Arix Bioscience PLC (ARIX)
Transaction in own shares
25-March-2021 / 16:57 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Transaction in own shares
LONDON, 25 March 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on
investing in and building breakthrough biotech companies, today announces that it purchased the following number of its
ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a
buyback programme announced on 22 March 2021.
Date of purchase 25 March 2021
Aggregate number of shares purchased 78,000
Highest price paid per share 195.00p
Lowest price paid per share 191.00p
Average price paid per share 192.82p
Arix intends to retain the purchased shares in treasury.
Following settlement of the above purchase, Arix will have 135,308,653 ordinary shares of 0.001 pence each in issue (excluding 301,000 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Transaction Date Transaction Time Volume Price (GBp) Platform Transaction Reference Number 25/03/2021 09:01:41 10,000 192.50 London Stock Exchange 00231912863TRLO0 25/03/2021 12:50:40 2,500 192.00 London Stock Exchange 00231961550TRLO0 25/03/2021 13:31:39 10,000 192.40 London Stock Exchange 00231971407TRLO0 25/03/2021 14:40:58 25,000 192.00 London Stock Exchange 00231997286TRLO0 25/03/2021 14:53:35 6,000 191.00 London Stock Exchange 00232003664TRLO0 25/03/2021 15:42:48 12,925 194.00 London Stock Exchange 00232036643TRLO0 25/03/2021 16:15:51 11,575 195.00 London Stock Exchange 00232058700TRLO0
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: HQCXNIX43 -----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071 Category Code: POS TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares Sequence No.: 96318 EQS News ID: 1178667 End of Announcement EQS News Service =------------------------------------------------------------------------------------
(END) Dow Jones Newswires
March 25, 2021 12:58 ET (16:58 GMT)
